Literature DB >> 17687663

Mirtazapine for anorexia nervosa with depression.

Nik Ruzyanei Nik Jaafar1, Tuti Iryani Mohd Daud, Fairuz Nazri Abdul Rahman, Azlin Baharudin.   

Abstract

OBJECTIVE: To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain.
METHOD: We present an outpatient case report of anorexia nervosa with depression. The patient's subsequent progress was recorded.
RESULTS: The patient gained 2.5 kg within 3 months to eventually attain a body mass index of 15 after 5 months. Her depression achieved full remission at 6 weeks of treatment.
CONCLUSIONS: Mirtazapine is the choice medication in this case. However, treating depression requires caution, given these patients' physical vulnerability. Controlled trials of Mirtazapine for anorexia nervosa are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687663     DOI: 10.1080/00048670701517983

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  2 in total

1.  A review of medication use for children and adolescents with eating disorders.

Authors:  Jennifer Couturier; James Lock
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-11

Review 2.  Canadian practice guidelines for the treatment of children and adolescents with eating disorders.

Authors:  Jennifer Couturier; Leanna Isserlin; Mark Norris; Wendy Spettigue; Melissa Brouwers; Melissa Kimber; Gail McVey; Cheryl Webb; Sheri Findlay; Neera Bhatnagar; Natasha Snelgrove; Amanda Ritsma; Wendy Preskow; Catherine Miller; Jennifer Coelho; Ahmed Boachie; Cathleen Steinegger; Rachel Loewen; Techiya Loewen; Elizabeth Waite; Catherine Ford; Kerry Bourret; Joanne Gusella; Josie Geller; Adele LaFrance; Anick LeClerc; Jennifer Scarborough; Seena Grewal; Monique Jericho; Gina Dimitropoulos; David Pilon
Journal:  J Eat Disord       Date:  2020-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.